<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01310465</url>
  </required_header>
  <id_info>
    <org_study_id>FudanU-0457034</org_study_id>
    <nct_id>NCT01310465</nct_id>
  </id_info>
  <brief_title>The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion</brief_title>
  <official_title>The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many patients who have lumbar degenerative disease suffer from osteoporosis or reduced bone
      mass or low bone mineral density. Among patients with lumbar degenerative disease, some need
      fusion surgery. But conditions of osteoporosis or low bone mineral density slow down the rate
      of bone fusion, reduce the success of bone fusion, and ultimately affect the overall
      effectiveness of surgery. Zoledronic acid is an effective anti-osteoporotic. Many researchers
      dispute if zoledronic acid can promote the healing of long bone fractures. But few
      researchers focus on the effect of zoledronic acid to lumbar fusion. In this study, we select
      patients with lumbar degenerative disease who have had lumbar interbody fusion surgery. Three
      days postoperatively, the patients were randomized to either one infusion of zoledronic acid
      or sodium chloride intravenously. We follow all these patients for 6 months. During this
      time, we detect bone metabolism and bone fusion of these patients. At last, we can tell if
      zoledronic acid can modify bone metabolism and promote bone fusion.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">April 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Image Changes of Lumbar Fusion</condition>
  <condition>Bone Turnover Markers</condition>
  <condition>Bone Mineral Density</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three days postoperatively, patients in this group are given one infusion of zoledronic acid intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three days postoperatively, patients in this group are given one infusion of sodium chloride intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <description>zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium chloride</intervention_name>
    <description>sodium chloride, 100ml, intravenous, one time at three days postoperatively</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with lumbar degenerative disease who have had lumbar interbody fusion surgery

          -  Age 50-70 years old

          -  Willing to sign informed consent

        Exclusion Criteria:

          -  Application of strontium ranelate, sodium fluoride or parathyroid hormone

          -  Application of bisphosphonates more than 8 weeks during 2 years preoperatively

          -  Suffering from bone fracture during 3 months preoperatively

          -  Urinary creatinine clearance rate less than 35mL/min

          -  Serum calcium concentrations greater than 2.75mmol/L or less than 2.00mmol/L

          -  Pregnancy or breast-feeding women

          -  Suffering from cancer or other diseases that may be expected to live less than a year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chao Li, bachelor</last_name>
    <phone>15202183944</phone>
    <email>lichao0457034@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan hospital of Fudan university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao Li, bachlor</last_name>
      <phone>15202183944</phone>
      <email>lichao0457034@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chao Li, bachlor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.zs-hospital.sh.cn/</url>
    <description>Zhongshan Hospital</description>
  </link>
  <reference>
    <citation>Col√≥n-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C; HORIZON Recurrent Fracture Trial. Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int. 2011 Aug;22(8):2329-36. doi: 10.1007/s00198-010-1473-1. Epub 2010 Dec 9.</citation>
    <PMID>21153021</PMID>
  </reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>March 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2011</study_first_posted>
  <last_update_submitted>March 7, 2011</last_update_submitted>
  <last_update_submitted_qc>March 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jian Dong</name_title>
    <organization>Department of Orthopedics of Zhongshan Hospital of Fudan University,</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

